Enoblituzumab, previously known as TJ-271 or MGA271, represents an novel therapeutic targeting CD33, an surface protein found predominantly on blood populations. The molecule operates as an dual-action molecule, at https://montycbmo885913.aboutyoublog.com/52423093/enoblituzumab-a-deep-dive-into-tj-271-and-mga271